Resistance to thyroid hormone (RTH) has been reported in more than 500 families since the first thyroid hormone receptor beta (TRβ) gene mutation was identified in 1989 [1]. The disease has an autosomal dominant mode of inheritance, and approximately 140 different mutations of the TRβ gene have been identified. It is estimated that there are more than 40,000 RTH patients worldwide [2]. No TRβ mutations are observed in approximately 15% of RTH cases [1], and the resistance in these cases is caused by mutations in the monocarboxylate transporter 8 (MCT8) [3] and the thyroid hormone receptor alpha (TRα) genes [4]. There are an estimated 3,000 cases in Japan of RTH associated with TRβ gene mutations. Here we report a case of RTH without a family history, diagnosed by persistent palpitations.

Case report

The patient was a 44-year-old man who had been prone to episodes of nervousness since early childhood. Although a physical examination showed no obvious abnormalities, the patient reported experiencing periods of palpitations since April 2009 that were not induced by any known stimuli (no other signs of thyrotoxicosis) and presented to the Cardiology Department at our hospital because of exacerbation of palpitations. Electrocardiography showed sinus tachycardia, with
a rate of 160 /min at the time of presentation, which disappeared following intravenous administration of β-blocker. The results of blood tests indicated inappropriate secretion of thyroid stimulating hormone (SITSH): thyroid stimulating hormone (TSH) 1.94 μIU/ml, free triiodothyronine (FT3) 4.47 pg/ml and free thyroxine (FT4) 2.18 ng/dl. Based on these findings, the patient was referred to our department in July 2009. Follow-up examinations showed persistence of SITSH (TSH 2.54 μIU/ml, FT4 3.00 ng/dl). Accordingly, the patient was admitted to our department in August 2009 for further examination and treatment.

On admission, a thyroid autoantibody test showed negative results (Table 1), and a physical examination showed no thyroid enlargement and no evidence of increased blood flow on ultrasonography. Pituitary magnetic resonance imaging (MRI) showed no evidence of tumor, and a thyrotropin-releasing hormone (TRH) stimulation test showed a normal TSH response (Table 2). No increases in sex-hormone binding globulin (SHBG) or TSH-α subunit were noted, thus the presence of a TSH-producing adenoma (TSHoma) was ruled out (although a T3 inhibition test was not performed). The family history was negative for RTH. The patient was followed up while on treatment with β-blockers at the onset of palpitations. The patient visited our department again in October 2013 because of persistent palpitations. Due to the persistent SITSH (TSH 2.43 μIU/ml, FT3 4.90 pg/ml, FT4 2.25 ng/dl), we obtained informed consent and performed a genetic analysis for TRβ mutations for a definitive diagnosis.

<table>
<thead>
<tr>
<th>Table 1. Laboratory data on admission</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CBC</strong></td>
</tr>
<tr>
<td>Leukocytes (/mm³)</td>
</tr>
<tr>
<td>Neutrophils (%)</td>
</tr>
<tr>
<td>Eosinophils (%)</td>
</tr>
<tr>
<td>Basophils (%)</td>
</tr>
<tr>
<td>Lymphocytes (%)</td>
</tr>
<tr>
<td>Monocytes (%)</td>
</tr>
<tr>
<td>Erythrocytes (×10⁶/mm³)</td>
</tr>
<tr>
<td>Hemoglobin (g/dl)</td>
</tr>
<tr>
<td>Hematocrit (%)</td>
</tr>
<tr>
<td>Platelets count (×10³/mm³)</td>
</tr>
<tr>
<td><strong>Urine</strong></td>
</tr>
<tr>
<td>pH</td>
</tr>
<tr>
<td>glucose</td>
</tr>
<tr>
<td>protein</td>
</tr>
<tr>
<td>ketone</td>
</tr>
<tr>
<td>occult blood</td>
</tr>
</tbody>
</table>

The result showed that proline had mutated to alanine (P453A) in exon 10 (Fig. 1). The above findings confirmed the diagnosis of RTH. Since the patient’s parents and other members of the extended family had already died (causes of death unknown), we performed genetic screening on the patient only. The patient is currently being followed-up with symptomatic treatment of palpitation episodes with β-blockers.

**Discussion**

We reported a patient of RTH with a negative family history who was diagnosed, based on persistent palpitations, to have a TRβ mutation causing the substitution of alanine for proline 453 (P453A). To date, the P453A mutation has been reported in only one family in Japan [5] and 8 families worldwide [6–10]. The P453A mutation results in decreased affinity of TRβ for T3, and the mutant protein has only 17% T3 affinity compared to the wild-type [8, 9]. Several cases have been reported, with substitution of proline with alanine, serine or threonine at position 453. Goiter is a common manifestation of RTH and is observed in 66–95% of patients [11]. Approximately 70% of RTH patients with a P453A mutation also develop goiter, although that was absent in our case (Table 3). Although goiter is not a clinical concern in general, when it is of clinical significance, administration of a large single dose of synthetic T3 preparation at one-day intervals is reported to result in almost complete inhibition of TSH secretion and reduction of goiter [12].

T3 acts through TRα in the cardiac muscle, and many patients with RTH complain of palpitations. The patient reported here also complained mainly of palpitations, as has been reported in other RTH cases with the P453A mutation. However, as reported by Weiss et al [13], the clinical disease type is not related to the gene mutation.

RTH can be clinically classified as generalized RTH (GRTH) or pituitary RTH (PRTH). RTH with a normal physical condition or a hypothyroid condition is classified as GRTH, while RTH with thyrotoxicosis is classified as PRTH. The patient reported herein had tachycardia as thyrotoxicosis, so could be classified as PRTH.
Although FT4 values vary among RTH cases, these values are reportedly associated with impairment of T3 binding activity [13], except in cases of reduced hormone affinity and dominant negative. The impairment of T3 binding activity affinity in patients with a P453A mutation is 17% of that observed in the wild type.

RTH is a condition in which the reduced tissue responsiveness to thyroid hormone is compensated for by elevated TSH and FT4 levels [1]. Therefore, administration of anti-thyroid drugs or surgical treatment may result in thyroid malfunction, necessitating continuous treatment thereafter. Various mistreatments of RTH cases with P453A mutation have been reported (Table 3) [6, 7, 10], and a recent study that reported painless thyroiditis complicating P453A mutations highlights the need for careful judgment in making an appropriate treatment decision [5]. It is important to monitor clinical symptoms carefully and to maintain the values of FT4 and FT3 below the upper limits and to keep the TSH level within the normal range.

Treatment of RTH is different from that of Graves’ disease and TSHoma, therefore even if the patient has a negative family history of RTH, genetic analysis should be performed when SITSH persists and TSHoma can be ruled out.

Acknowledgments

The authors thank Dr. Y. Hayashi and Y. Murata from Nagoya University for gene analysis of TRβ.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Refetoff S (2008): Resistance to thyroid hormone: one of several defects causing reduced sensitivity to thyroid hormone. Nat Clin Pract Endocrinol Metab 4: 1
5. Taniyama M, Otsuka F, Tozaki T & Ban Y (2013): Thyroid profiles in a patient with resistance to thyroid hormone and episodes of thyrotoxicosis, including repeated painless thyroiditis. Thyroid 23: 898–901

Table 3. Clinical features of reported RTH patients with P453A mutation

<table>
<thead>
<tr>
<th>Age at diagnosis/sex</th>
<th>Country</th>
<th>goiter</th>
<th>palpitation</th>
<th>Other family members with RTH</th>
<th>Mistreatment</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>40/F</td>
<td>New Zealand</td>
<td>+</td>
<td>+</td>
<td>Daughter</td>
<td>ATD·RAI</td>
<td>[6]</td>
</tr>
<tr>
<td>37/F</td>
<td>Turkey</td>
<td>+</td>
<td>+</td>
<td>Son</td>
<td>ATD thyroidectomy</td>
<td>[7]</td>
</tr>
<tr>
<td>45/M</td>
<td>United Kingdom</td>
<td>unknown</td>
<td>unknown</td>
<td>unknown</td>
<td>unknown</td>
<td>[8]</td>
</tr>
<tr>
<td>46/F</td>
<td>France</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>[9]</td>
</tr>
<tr>
<td>18/F</td>
<td>Turkey</td>
<td>+</td>
<td>–</td>
<td>Mother</td>
<td>–</td>
<td>[10]</td>
</tr>
<tr>
<td>48/F</td>
<td>–</td>
<td>+</td>
<td>unknown</td>
<td>Daughter</td>
<td>thyroidectomy</td>
<td>[10]</td>
</tr>
<tr>
<td>44/F</td>
<td>Japan</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>[5]</td>
</tr>
<tr>
<td>44/M</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>our case</td>
</tr>
</tbody>
</table>

RTH: resistance to thyroid hormone, ATD: anti thyroid drug, RAI: radioactive iodine
12. Anselmo J & Refetoff S (2004): Regression of a large goiter in a patient with resistance to thyroid hormone by every other day treatment with triiodothyronine. Thyroid 14: 71–74
繰り返す動悸を契機に診断に至った家族歴を有さない甲状腺ホルモン不応症の1例

黒住 旭1, 岡田 洋右1, 新生 忠司1,2, 田中 良哉1

1産業医科大学 医学部 第1内科学講座
2九州労災病院 門司メディカルセンター 内科

要 旨：甲状腺ホルモン不応症(RTH)は、これまで約140種類の甲状腺ホルモン受容体ベータ(TRβ)遺伝子変異が同定されている。今回家族歴は有さないが、繰り返す動悸を契機にRTHの診断に至った中年男性の1例を経験したので報告する。TRβ遺伝子解析の結果、第10エクソン、453番目のプロリンからアラニンへの変異を認めた。RTHはバセドウ病やTSH(thyroid stimulating hormone)産生腫瘍(TSHoma)とは治療法がまったく異なるため、RTHの家族歴を有さなくても、不適切TSH分泌症候群が持続しTSHomaが否定的な場合には、積極的に遺伝子解析を行うことが重要である。

キーワード：甲状腺ホルモン不応症、甲状腺ホルモン受容体ベータ、不適切TSH分泌症候群。